Chenodeoxycholic acid stimulates glucagon-like peptide-1 secretion in patients after Roux-en-Y gastric bypass

Physiological Reports

Volumn 5, Issue 3, 2017, Pages

  Nielsen, Signe ^a,b   Svane, Maria S ^a,b   Kuhre, Rune E ^b   Clausen, Trine R ^c   Kristiansen, Viggo B ^a   Rehfeld, Jens F ^d   Holst, Jens J ^b   Madsbad, Sten ^a,b   Bojsen Moller, Kirstine N ^a,b  

^a HVIDOVRE HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c NOVO NORDISK A S   (Denmark)

^d Rigshospitalet   (Denmark)

Author keywords

Bile acids; GLP 1; PYY; Roux en Y gastric bypass

Indexed keywords

C PEPTIDE; CHENODEOXYCHOLIC ACID; CHOLECYSTOKININ; FIBROBLAST GROWTH FACTOR 19; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; NEUROTENSIN; PEPTIDE YY; PLACEBO; URSODEOXYCHOLIC ACID; BILE ACID; FGF19 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR;

ADULT; AREA UNDER THE CURVE RATIO; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART RATE; HORMONE RELEASE; HUMAN; INTESTINAL SECRETION; MALE; PROTEIN EXPRESSION; ROUX-EN-Y GASTRIC BYPASS; VISUAL ANALOG SCALE; BLOOD; CLINICAL TRIAL; GASTRIC BYPASS SURGERY; GLUCOSE BLOOD LEVEL; ORAL DRUG ADMINISTRATION; SECRETION (PROCESS);

ADMINISTRATION, ORAL; ADULT; BILE ACIDS AND SALTS; BLOOD GLUCOSE; C-PEPTIDE; CHENODEOXYCHOLIC ACID; CROSS-OVER STUDIES; FEMALE; FIBROBLAST GROWTH FACTORS; GASTRIC BYPASS; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; MALE; URSODEOXYCHOLIC ACID;

EID: 85013653320     PISSN: None     EISSN: 2051817X     Source Type: Journal    
DOI: 10.14814/phy2.13140     Document Type: Article

References (50)

1. Adrian, T. E., G. H. Ballantyne, W. E. Longo, A. J. Bilchik, S. Graham, M. D. Basson, et al. 1993. Deoxycholate is an important releaser of peptide YY and enteroglucagon from the human colon. Gut 34:1219–1224.
2. Adrian, T. E., S. Gariballa, K. A. Parekh, S. A. Thomas, H. Saadi, J. Al Kaabi, et al. 2012. Rectal taurocholate increases L cell and insulin secretion, and decreases blood glucose and food intake in obese type 2 diabetic volunteers. Diabetologia 55:2343–2347.
3. Ahmad, N. N., A. Pfalzer, and L. M. Kaplan. 2013. Roux-en-Y Gastric Bypass Normalizes the Blunted Postprandial Bile Acid Excursion Associated With Obesity. 37:1553–1559.
4. Bala, V., S. Rajagopal, D. P. Kumar, A. D. Nalli, S. Mahavadi, A. J. Sanyal, et al. 2014. Release of GLP-1 and PYY in response to the activation of G protein-coupled bile acid receptor TGR5 is mediated by Epac/PLC-ε pathway and modulated by endogenous H2S. Front. Physiol. 5:420.
5. Baud, G., M. Daoudi, T. Hubert, V. Raverdy, M. Pigeyre, E. Hervieux, et al. 2016. Bile diversion in roux-en-y gastric bypass modulates sodium-dependent glucose intestinal uptake. Cell Metab. 23:547–553.
6. Bojsen-Møller, K. N., C. Dirksen, N. B. Jørgensen, S. H. Jacobsen, A. K. Serup, P. H. Albers, et al. 2014. Early Enhancements of Hepatic and Later of Peripheral Insulin Sensitivity Combined With Increased Postprandial Insulin Secretion Contribute to Improved Glycemic Control After Roux-en-Y Gastric Bypass. Diabetes 63:1725–1737.
7. Brighton, C. A., J. Rievaj, R. E. Kuhre, L. L. Glass, K. Schoonjans, J. J. Holst, et al. 2015. Bile Acids Trigger GLP-1 Release Predominantly by Accessing Basolaterally Located G Protein-Coupled Bile Acid Receptors. Endocrinology 156:3961–3970.
8. Dirksen, C., N. B. Jørgensen, K. N. Bojsen-Møller, S. H. Jacobsen, D. L. Hansen, D. Worm, et al. 2012. Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass. Diabetologia 55:1890–1901.
9. Dirksen, C., M. Damgaard, K. N. Bojsen-Møller, N. B. Jørgensen, U. Kielgast, S. H. Jacobsen, et al. 2013a. Fast pouch emptying, delayed small intestinal transit, and exaggerated gut hormone responses after Roux-en-Y gastric bypass. Neurogastroenterol. Motil. 25:346–e255.
10. Dirksen, C., N. B. Jørgensen, K. N. Bojsen-Møller, U. Kielgast, S. H. Jacobsen, T. R. Clausen, et al. 2013b. Gut hormones, early dumping and resting energy expenditure in patients with good and poor weight loss response after Roux-en-Y gastric bypass. Int. J. Obes. 37:1452–1459.
11. Dutia, R., M. Embrey, C. S. O'Brien, R. A. Haeusler, K. K. Agénor, P. Homel, et al. 2015. Temporal changes in bile acid levels and 12α-hydroxylation after Roux-en-Y gastric bypass surgery in type 2 diabetes. Int. J. Obes. 1–8.
12. Eissele, R., R. Göke, S. Willemer, H. P. Harthus, H. Vermeer, R. Arnold, et al. 1992. Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur. J. Clin. Invest. 22:283–291.
13. Grunddal, K. V., C. F. Ratner, B. Svendsen, F. Sommer, M. S. Engelstoft, A. N. Madsen, et al. 2016. Neurotensin Is Coexpressed, Coreleased, and Acts Together With GLP-1 and PYY in Enteroendocrine Control of Metabolism. Endocrinology 157:176–194.
14. Hansen, M., M. J. Scheltema, D. P. Sonne, J. S. Hansen, M. Sperling, J. F. Rehfeld, et al. 2016. Effect of chenodeoxycholic acid and the bile acid sequestrant colesevelam on glucagon-like peptide-1 secretion. Diabetes Obes. Metab. 18:571–580.
15. Holst, J. J., J. H. Pedersen, F. Baldissera, and F. Stadil. 1983. Circulating glucagon after total pancreatectomy in man. Diabetologia 25:396–399.
16. Hvidberg, A., M. T. Nielsen, J. Hilsted, C. Orskov, and J. J. Holst. 1994. Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man. Metabolism 43:104–108.
17. Jacobsen, S. H., S. C. Olesen, C. Dirksen, N. B. Jørgensen, K. N. Bojsen-Møller, U. Kielgast, et al. 2012. Changes in gastrointestinal hormone responses, insulin sensitivity, and beta-cell function within 2 weeks after gastric bypass in non-diabetic subjects. Obes. Surg. 22:1084–1096.
18. Jansen, P. L. M., J. van Werven, E. Aarts, F. Berends, I. Janssen, J. Stoker, et al. 2011. Alterations of hormonally active fibroblast growth factors after Roux-en-Y gastric bypass surgery. Dig. Dis. 29:48–51.
19. Jørgensen, N. B., S. H. Jacobsen, C. Dirksen, K. N. Bojsen-Møller, L. Naver, L. Hvolris, et al. 2012. Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with Type 2 diabetes and normal glucose tolerance. Am. J. Physiol. Endocrinol. Metab. 303:E122–E131.
20. Jørgensen, N. B., C. Dirksen, K. N. Bojsen-Møller, S. H. Jacobsen, D. Worm, D. L. Hansen, et al. 2013. Exaggerated glucagon-like peptide 1 response is important for improved β-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes. Diabetes 62:3044–3052.
21. Jørgensen, N. B., C. Dirksen, K. N. Bojsen-Møller, V. B. Kristiansen, B. S. Wulff, D. Rainteau, et al. 2015. Improvements in Glucose Metabolism Early After Gastric Bypass Surgery Are Not Explained by Increases in Total Bile Acids and Fibroblast Growth Factor 19 Concentrations. J. Clin. Endocrinol. Metab. 100:E396–E406.
22. Kawamata, Y., R. Fujii, M. Hosoya, M. Harada, H. Yoshida, M. Miwa, et al. 2003. A G protein-coupled receptor responsive to bile acids. J. Biol. Chem. 278:9435–9440.
23. Kohli, R., and R. J. Seeley. 2013. Diabetes: the search for mechanisms underlying bariatric surgery. Nat. Rev. Endocrinol. 9:572–574.
24. Kohli, R., D. Bradley, K. D. Setchell, J. C. Eagon, N. Abumrad, and S. Klein. 2013a. Weight loss induced by Roux-en-Y gastric bypass but not laparoscopic adjustable gastric banding increases circulating bile acids. J. Clin. Endocrinol. Metab. 98:E708–E712.
25. Kohli, R., K. D. Setchell, M. Kirby, A. Myronovych, K. K. Ryan, S. H. Ibrahim, et al. 2013b. A surgical model in male obese rats uncovers protective effects of bile acids post-bariatric surgery. Endocrinology 154:2341–2351.
26. Kuhre, R. E., L. E. Bechmann, N. J. Wewer Albrechtsen, B. Hartmann, and J. J. Holst. 2015. Glucose stimulates neurotensin secretion from the rat small intestine by mechanisms involving SGLT1 and GLUT2, leading to cell depolarization and calcium influx. Am. J. Physiol. Endocrinol. Metab. 308:E1123–E1130.
27. Kuhre, R. E., N. J. Wewer Albrechtsen, O. Larsen, S. L. Jepsen, A. Adriaenssen, F. Reimann, et al. 2016. Bile acids stimulate secretion of GLP-1 and PYY through activation of basolateral L-cell GPBAR1 receptors but have no direct effect on glucagon or insulin secretion. Diabetologia 59 (Suppl 1). Abstract 533.
28. Lund, A., J. I. Bagger, N. J. Wewer Albrechtsen, M. Christensen, M. Grøndahl, B. Hartmann, et al. 2016. Evidence of Extrapancreatic Glucagon Secretion in Man. Diabetes 65:585–597.
29. Ma, H., and M. E. Patti. 2014. Bile acids, obesity, and the metabolic syndrome. Best Pract. Res. Clin. Gastroenterol. 28:573–583.
30. Madsbad, S., C. Dirksen, and J. J. Holst. 2014. Mechanisms of changes in glucose metabolism and bodyweight after bariatric surgery. Lancet Diabetes Endocrinol. 2:152–164.
31. Meyer-Gerspach, A. C., R. E. Steinert, S. Keller, A. Malarski, F. H. Schulte, and C. Beglinger. 2013. Effects of chenodeoxycholic acid on the secretion of gut peptides and fibroblast growth factors in healthy humans. J. Clin. Endocrinol. Metab. 98:3351–3358.
32. Nakatani, H., K. Kasama, T. Oshiro, M. Watanabe, H. Hirose, and H. Itoh. 2009. Serum bile acid along with plasma incretins and serum high-molecular weight adiponectin levels are increased after bariatric surgery. Metabolism 58:1400–1407.
33. Ørskov, C., L. Rabenhøj, A. Wettergren, H. Kofod, and J. J. Holst. 1994. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 43:535–539.
34. Pories, W. J., M. S. Swanson, K. G. MacDonald, S. B. Long, P. G. Morris, B. M. Brown, et al. 1995. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann. Surg. 222:339–350; discussion 350–2.
35. Pournaras, D. J., C. Glicksman, R. P. Vincent, S. Kuganolipava, J. Alaghband-Zadeh, D. Mahon, et al. 2012. The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control. Endocrinology 153:3613–3619.
36. Rehfeld, J. F. 1998. Accurate measurement of cholecystokinin in plasma. Clin. Chem. 44:991–1001.
37. Renga, B., A. Mencarelli, P. Vavassori, V. Brancaleone, and S. Fiorucci. 2010. The bile acid sensor FXR regulates insulin transcription and secretion. Biochim. Biophys. Acta 1802:363–72.
38. Ryan, K. K., V. Tremaroli, C. Clemmensen, P. Kovatcheva-Datchary, A. Myronovych, R. Karns, et al. 2014. FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature 509:183–188.
39. Schauer, P. R., D. L. Bhatt, J. P. Kirwan, K. Wolski, S. A. Brethauer, S. D. Navaneethan, et al. 2014. Bariatric surgery versus intensive medical therapy for diabetes–3-year outcomes. N. Engl. J. Med. 370:2002–2013.
40. Schmidt, J. B., S. D. Pedersen, N. T. Gregersen, L. Vestergaard, M. S. Nielsen, C. Ritz, et al. 2016. Effects of RYGB on energy expenditure, appetite and glycaemic control: a randomized controlled clinical trial. Int. J. Obes. 40:281–290.
41. Sjöström, L. 2013. Review of the key results from the Swedish Obese Subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery. J. Intern. Med. 273:219–234.
42. Steinert, R. E., R. Peterli, S. Keller, A. C. Meyer-Gerspach, J. Drewe, T. Peters, et al. 2013. Bile acids and gut peptide secretion after bariatric surgery: a 1-year prospective randomized pilot trial. Obesity 21:E660–E668.
43. Svane, M. S., K. N. Bojsen-Møller, S. Nielsen, N. B. Jørgensen, C. Dirksen, F. Bendtsen, et al. 2016. Effects of endogenous GLP-1 and GIP on glucose tolerance after Roux-en-Y gastric bypass surgery. Am. J. Physiol. Endocrinol. Metab. 310:E505–E514.
44. Svendsen, B., J. Pedersen, N. J. W. Albrechtsen, B. Hartmann, S. Toräng, J. F. Rehfeld, et al. 2015. An analysis of cosecretion and coexpression of gut hormones from male rat proximal and distal small intestine. Endocrinology 156:847–857.
45. Toräng, S., K. N. Bojsen-Møller, M. S. Svane, B. Hartmann, M. M. Rosenkilde, S. Madsbad, et al. 2016. In vivo and in vitro degradation of peptide YY3-36 to inactive peptide YY3-34 in humans. Am. J. Physiol. Regul. Integr. Comp. Physiol. 310:R866–R874.
46. Trabelsi, M., M. Daoudi, J. Prawitt, S. Ducastel, V. Touche, S. I. Sayin, et al. 2015. Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells. Nat. Commun. 6:7629.
47. Werling, M., R. P. Vincent, G. F. Cross, H.-U. Marschall, L. Fändriks, H. Lönroth, et al. 2013. Enhanced fasting and post-prandial plasma bile acid responses after Roux-en-Y gastric bypass surgery. Scand. J. Gastroenterol. 48:1257–1264.
48. Wewer Albrechtsen, N. J., R. E. Kuhre, S. Toräng, and J. J. Holst. 2016. The intestinal distribution pattern of appetite- and glucose regulatory peptides in mice, rats and pigs. BMC Res. Notes 9:60.
49. Wu, T., M. J. Bound, S. D. Standfield, B. Gedulin, K. L. Jones, M. Horowitz, et al. 2013a. Effects of rectal administration of taurocholic acid on glucagon-like peptide-1 and peptide YY secretion in healthy humans. Diabetes Obes. Metab. 15:474–477.
50. Wu, T., M. J. Bound, S. D. Standfield, K. L. Jones, M. Horowitz, and C. K. Rayner. 2013b. Effects of taurocholic acid on glycemic, glucagon-like peptide-1, and insulin responses to small intestinal glucose infusion in healthy humans. J. Clin. Endocrinol. Metab. 98:718–722.